End Hep C SF is a multi-sector collective impact* initiative that utilizes evidence-based practices, community wisdom, and the creative leveraging of resources to work toward hepatitis C elimination in San Francisco. San Francisco has a history of innovative and ambitious public health efforts. End Hep C SF emerges from that history to tackle an epidemic that kills more Americans than the deaths from sixty other reportable infectious diseases, including HIV, pneumococcal disease, and tuberculosis, combined.
San Francisco is impacted profoundly by the hepatitis C virus (HCV), a communicable liver disease that is a significant driver of morbidity, liver cancer, and death.
The availability of highly effective, well-tolerated oral HCV therapy gives us the remarkable ability to cure HCV in nearly all people living with the virus. We now have the tools to greatly reduce the negative health consequences of HCV, to break the cycle of forward transmission through cure as prevention, and to ultimately eliminate HCV in San Francisco.
To realize the potential of modern HCV therapy, we have established End Hep C SF. Our long-term strategic plan is to lay the foundation for HCV elimination in San Francisco through a comprehensive approach based on three pillars.
End Hep C SF is guided by a Steering Committee and four topic-specific work groups that recommend action steps to the Steering Committee. The Work Groups are comprised of individuals affected by HCV, healthcare and social service providers, community advocates, health department representatives, and other stakeholders.
The Steering Committee is comprised of people who have expertise around hepatitis C and share the vision of hepatitis C elimination. Members represent several organizations and practices in San Francisco that are on the forefront of hepatitis C testing, linkage, treatment, and advocacy.
Current members of the Steering Committee include:
|Katie Burk||MPH, SFDPH|
|Kelly Eagen||MD, SFDPH|
|Rena Fox||MD, UCSF, VA|
|Theresa Hughes||Hughes Health Care Disparities|
|Emalie Huriaux||MPH, Project Inform & CalHEP|
|Isaac Jackson||Community Member|
|Annie Luetkemeyer||MD, ZSFG, UCSF|
|Alfredta Nesbitt||Bayview Hunters Point Foundation|
|Kyriell Noon||Glide Foundation|
|Robin Roth||San Francisco Hepatitis C Task Force|
|Mandana Khalili||MD, UCSF|
|Norah Terrault||MD, UCSF|
|Rachel McLean||MPH, CDPH|
|Janetta Johnson||TGI Justice|
Work groups are open to the public. We welcome anyone with lived experience with hepatitis C, people who work on hepatitis C related issues professionally, and anyone who wants to learn more about hepatitis C. To learn more about the initiative or to get involved email Katie Burk. You can also download our Vision Statement and Sign-On Sheet.
Research and Surveillance
The Research and Surveillance work group is comprised of researchers and epidemiologists who work on studies and surveillance related to hepatitis C. This group is broaching the question of how to best combine resources and information to understand the hepatitis C burden in San Francisco and to measure the progress we make towards eliminating hepatitis C.
Testing and Linkage
The Testing and Linkage work group is comprised of people who work for agencies that offer community-based hepatitis C testing and linkage services. These groups address the issue of how to identify and support marginalized San Franciscans who are most at risk for hepatitis C, yet among the least likely to be connected to services.
The Treatment Access work group is largely comprised of clinicians, pharmacists, and other direct service staff. This group focuses on initiatives to improve access to hepatitis C treatments for San Franciscans who receive care in both the public and private sectors. Another large focus of this group includes innovative treatment delivery mechanisms for patients in substance use treatment facilities, shelters, and occupancy hotels.
Prevention of Infection and Reinfection
The Prevention of infection and reinfection group is comprised of direct service staff and clinicians representing syringe access and methadone programs as well as medical clinics. This group works on refining of hepatitis C prevention messaging and developing message dissemination strategies.
*Collective Impact is a framework to tackle deeply entrenched and complex social problems. It is an innovative and structured approach to making collaboration work across government, business, philanthropy, non-profit organizations and citizens to achieve significant and lasting social change.
Send us a message
- End Hep C SF
- Hep C 101